News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
MDCO bullish 54.07
bull flag
normal chart
log chart
Yea... cash flow analyses imply Medicines Co $MDCO is 18% overvalued b4 earnings Wednesday:
Fair Value Source
LOL,..do you even keep up with the latest developments of this company ?
are you even a shareholder oh bringer of negative (fake) news?
really. "UNPROFITABLE SCAM" based on what ? your opinion. you post a few words of discouragement and the MDCO forum is obliged to believe you ? LOL. 
i guess the MDCO principals/insiders are not in the same loop of info as your privy in that they parallel VRX,...
hmmm,..explain this ,....in Dec 16 insiders bought over 640,000 shares at average market price of $34.05.
for this $30 stock that totals about $12,870,000 in cash,...
so they, the principals, have some skin in the game.
my prediction,..
their products will hit big !!!! and in case you don't follow the company results and it's milestones
,...The company is developing a compound called Inclisiran that looks really promising. This is one of the new types of cholesterol-lowering drugs and has significant potential. Insiders certainly believe they have a valuable asset.
so why would company insiders buy millions of dollars in their own company stock IF there is nothing to be had as you suggest ? why ?
and they bought in Dec'16 when the price was $33,..now the price is $45,...ya think they had an idea that things will start moving in a positive direction ?
yea,...i guess they need to get in iHub MDCO forum to get the real deal from you,....LOL
Medicines Company has thrown itself into R&D since it faced a patent cliff some years ago. Results have been good, with approval for its skin-infection treatment Orbactiv in 2014, its blood-thinner Kengreal and fentanyl patch Ionsys in 2015, and positive topline results from a phase III study its urinary tract infection drug carbavance which was announced in June 2016. Carbavance will have an NDA submitted early 2017. This is a lot of good news, and if inclisiran can also show success, then MDCO will be looking at many years of strong revenue growth from its products and pipeline.
|
Followers
|
9
|
Posters
|
|
|
Posts (Today)
|
0
|
Posts (Total)
|
232
|
|
Created
|
05/13/09
|
Type
|
Free
|
| Moderators | |||
